N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP) and ketamine can evoke psychotic symptoms in normal individuals and schizophrenic patients. Here, we have examined the effects of PCP (5 mg/kg) and ketamine (25 mg/kg) on the efflux of serotonin (5-HT) in the medial prefrontal cortex (mPFC) and their possible blockade by the antipsychotics, clozapine, olanzapine and haloperidol, as well as ritanserin (5-HT 2A/2C receptor antagonist) and prazosin (a 1 -adrenoceptor antagonist). The systemic administration, but not the local perfusion, of the two NMDA receptor antagonists markedly increased the efflux of 5-HT in the mPFC. The atypical antipsychotics clozapine (1 mg/kg) and olanzapine (1 mg/kg), and prazosin (0.3 mg/kg), but not the classical antipsychotic haloperidol (1 mg/kg), reversed the PCP-and ketamine-induced increase in 5-HT efflux. Ritanserin (5 mg/kg) was able to reverse only the effect of PCP. These findings indicate that an increased serotonergic transmission in the mPFC is a functional consequence of NMDA receptor hypofunction and this effect is blocked by atypical antipsychotic drugs.
Introduction
The hypothesis of the N-methyl-D-aspartate (NMDA) receptor hypofunction in schizophrenia stems from the observation that NMDA receptor antagonists such as phencyclidine (PCP) and ketamine can evoke psychotic symptoms in normal individuals and aggravate them in schizophrenic patients (for review, see Krystal et al., 2003) . For these reasons, NMDA receptor antagonists have been used in experimental animals to model neurochemical and behavioural changes that occur in schizophrenia. Thus, systemic administration of PCP or dizocilpine (MK-801) increases the firing of neurons of the medial prefrontal cortex (mPFC) and causes hyperlocomotion and stereotypies ( Jackson et al., 2004 ; Jodo et al., 2003 ; Suzuki et al., 2002) .
However, microiontophoretically applied PCP does not alter either mPFC cell firing or hyperlocomotion (Suzuki et al., 2002) , which suggests that the NMDA receptor antagonists turn on mPFC neurons through the stimulation of excitatory inputs from brain areas outside the mPFC. NMDA receptor antagonists have also been shown to increase extracellular glutamate (Abekawa et al., 2003 ; Lorrain et al., 2003 ; Moghaddam et al., 1997) , dopamine (Adams and Moghaddam, 1998 ; Mathé et al., 1999 ; Schmidt and Fadayel, 1996) , and serotonin (5-HT) (Adams and Moghaddam, 2001 ; Martin et al., 1998a ; Millan et al., 1999) in the mPFC. The source of this glutamate is presently unknown, but it has been proposed that NMDA receptor antagonists may block a tonic inhibitory influence of c-aminobutyric acid (GABA) neurons over an excitatory projection to the mPFC ( Jodo et al., 2005 ; Krystal et al., 2003 ; Lorrain et al., 2003 ; Moghaddam et al., 1997) . The increases in dopamine and 5-HT release are probably due to increments in dopaminergic (Pawlowski et al., 1990 ; Schmidt and Fadayel, 1996) and serotonergic (Lejeune et al., 1994) cell firing in the ventral tegmental area and the dorsal raphe nucleus respectively. This latter activation could result from an enhanced glutamatergic output from the mPFC neurons, including those projecting to the dorsal raphe nucleus. Indeed, the electrical or pharmacological stimulation of the mPFC increases serotonergic transmission in the dorsal raphe nucleus Martín-Ruiz et al., 2001 ). Nevertheless, a local effect of NMDA receptor antagonists in the dorsal raphe nucleus cannot be ruled out (Callado et al., 2000) .
Although a hyperactive serotonergic transmission in the mPFC has been implicated in schizophrenia (Meltzer, 1989) and in the hyperlocomotion induced by a reduced NMDA receptor function (Miyamoto et al., 2001 ), the precise role of cortical 5-HT on these effects remains to be determined. However, a relationship between 5-HT and schizophrenia stems from two main observations. First, 5-HT 2A/2C receptor agonists elicit hallucinogenic states in humans resembling those present in positive symptomatology (GouzoulisMayfrank et al., 1998) , and markedly increase the firing rate of pyramidal neurons in the mPFC (Puig et al., 2003) . Likewise, the selective activation of 5-HT 2A receptors in rodent mPFC increases local 5-HT release (Amargó s-Bosch et al., 2004 ; Bortolozzi et al., 2003 ; Martín-Ruiz et al., 2001 ; Puig et al., 2003) , which could point to an activation of mPFC serotonergic transmission in the illness. Second, atypical antipsychotics are effective 5-HT 2A receptor antagonists. In previous studies we have shown that antipsychotic drugs reverse the increase of the local extracellular 5-HT induced by the pharmacological stimulation of the mPFC with 5-HT 2A and a 1 -adrenergic receptor agonists Bortolozzi et al., 2003) . In the present work, we have examined the effects of clozapine, olanzapine and haloperidol on the efflux of 5-HT in the mPFC elicited by PCP and ketamine. In an attempt to understand the contribution of 5-HT 2A/2C and a 1 -adrenergic receptors in the action of these antipsychotic drugs, the effects of ritanserin and prazosin were also tested.
Materials and methods

Animals
Male Wistar rats (Iffa-Credo, Lyon, France) weighing 250-280 g were used. They were maintained on a 12-h light/dark cycle (lights on at 07:00 hours) and housed three per cage before surgery and individually after surgery. Food and water were always freely available. All experimental procedures were carried out in strict accordance with European Communities Council 
Microdialysis procedures
Concentric dialysis probes with a 4-mm long membrane were implanted under sodium pentobarbital anaesthesia (60 mg/kg i.p.) in the mPFC (AP +3.2 mm, L x0.8 mm, DV x6.0 mm ; from Bregma) according to Paxinos and Watson (1986) . Microdialysis experiments were conducted 20-24 h after surgery in freely moving rats by continuously perfusing probes with artificial cerebrospinal fluid containing 125 mM NaCl, 2.5 mM KCl, 1.26 mM CaCl 2 , 1.18 mM MgCl 2 and 1 mM citalopram, at a rate of 1.5 ml/min. Dialysate samples of 30 ml were collected every 20 min. After a 100-min stabilization period, four dialysate samples were collected to obtain basal 5-HT values before pharmacological treatment. At the completion of dialysis experiments, rats were given an overdose of sodium pentobarbital and a Fast Green solution was perfused through the dialysis probes to stain the surrounding tissue.
Biochemical determinations
The concentration of 5-HT in dialysate samples was determined by HPLC using a 3-mm octadecylsilica (ODS) column (7.5 cmr0.46 cm ; Beckman, San Ramon, CA, USA) and detected amperometrically with a Hewlett-Packard 1049 detector (Palo Alto, CA, USA) set at an oxidation potential of 0.6 V. The detection limit for 5-HT was estimated to be y1 fmol/ sample.
Experimental design
Basically, each experimental group started with the collection of four dialysate samples before drug administration (basal values). Then, a systemic injection (i.p. or s.c.) of saline or a drug (clozapine, olanzapine, haloperidol, prazosin or ritanserin), followed by the administration of a NMDA receptor antagonist (PCP or ketamine) or saline. To examine the local effects of NMDA receptor antagonists on extracellular 5-HT, successive increasing concentrations of PCP or ketamine were perfused for 80 min following the collection of four basal dialysate samples. The rats of the corresponding control group were perfused only with artificial cerebrospinal fluid.
Statistics
Data (mean¡S.E.M.) are expressed as fmol/fraction (uncorrected for recovery) and shown in figures as percentages of basal values, averaged from four fractions collected before treatment. The changes in dialysate 5-HT were analysed by two-way repeatedmeasures analysis of variance (ANOVA) with time and drug as factors. Area under the curve (AUC) was also calculated for the different treatments and expressed as percentage from the same period of control rats. When significant effects were found, post-hoc Newman-Keuls tests were used to compare the effects of each drug (or combination thereof) with the corresponding control group. The level of significance was set at p<0.05. For the sake of clarity, significant effects are depicted only in the AUC figures.
Results
The basal (pre-drug) concentration of 5-HT was not significantly different among all experimental groups and amounted to 37.6¡1.7 fmol/sample (n=126). The perfusion of PCP (10, 30, 100, 300 mM) or ketamine (100, 300, 1000 mM) in the mPFC did not change the local concentration of 5-HT (Figure 1 ). There was no difference between the three control groups used with regard to dialysate 5-HT. As described thoroughly in the literature, the systemic administration of PCP (5 mg/kg i.p.) and ketamine (25 mg/kg s.c.) to rats evoked a marked hyperlocomotion and stereotypies (behavioural observation). The concentration of 5-HT was also elevated significantly following the systemic administration of PCP (F 1,12 =17.28, p<0.002) and ketamine (F 1,12 =16.26, p<0.002). The effect of PCP was y20 % higher than that of ketamine, but this difference increase (F 1,11 =10.05, p<0.01) and olanzapine 1.0 mg/ kg s.c. produced no change in dialysate 5-HT. It was of note that none of these drugs evoked any gross behavioural change when administered alone (behavioural observation).
Discussion
The first main finding of this study is that the systemic administration of the NMDA receptor antagonists, PCP and ketamine, increases the efflux of 5-HT in the mPFC. To the best of our knowledge, this was previously shown for PCP (Adams and Moghaddam, 2001 ; Martin et al., 1998a ; Millan et al., 1999) , but not for ketamine. Likewise, previous work had shown increases in 5-hydroxyindoleacetic acid (5-HIAA) following MK-801 administration (Kashiwa et al., 1995 ; Lindefors et al., 1997 ; Lö scher et al., 1993) , which could be indicative of an enhanced 5-HT metabolism and/or release. Altogether these findings indicate that an increased serotonergic transmission in the mPFC is a general response to NMDA receptor hypofunction.
There does not seem to be differences between competitive and non-competitive NMDA receptor antagonists since both classes of compounds produce a similar activation of cortical serotonergic pathways (Lö scher et al., 1993) and 5-HT release (Ceglia et al., 2004) . Furthermore, this effect does not result from a direct action of these compounds on the mPFC because the local application of PCP or ketamine did not produce any change in the concentration of 5-HT. In line with our results, the intra-mPFC administration of NMDA receptor antagonists does not affect the local neuronal activity (Aghajanian and Marek, 2000 ; Jodo et al., 2003 ; Suzuki et al., 2002) , which suggests that the NMDA receptors responsible for such actions are located outside the mPFC. One possible site of action of NMDA receptor antagonists is the ventral hippocampus because the local application of PCP or MK-801 in this region increases the firing of pyramidal neurons in the mPFC (Jodo et al., 2005) . According to the hypothesis of the disinhibition of glutamatergic input to the mPFC (see Introduction), PCP and ketamine would increase glutamate release onto non-NMDA receptors in the mPFC (Krystal et al., 2003 ; Lorrain et al., 2003 ; Moghaddam et al., 1997) . SAL or PCP The stimulation of such non-NMDA receptors would, in turn, produce an enhanced glutamatergic output from the mPFC neurons, including those projecting to the dorsal raphe nucleus, thereby enhancing serotonergic cell firing and cortical 5-HT efflux. Therefore, the observed effects on 5-HT efflux would be secondary to a primary release of glutamate in the mPFC. In line with these results, the release of 5-HT in the mPFC evoked by the 5-HT 2A/2C receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or the a 1 -adrenoceptor agonist cirazoline was reversed by the a-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate receptor blockade and by the activation of mGluR2/3 receptors (Amargó s- Bortolozzi et al., 2003 ; Martín-Ruiz et al., 2001) . However, although this functional interplay between the mPFC and the dorsal raphe nucleus is well documented (Amargó s- Celada et al., 2001 ; Hajó s et al., 1998 ; Lucas et al., 2005 ; Martín-Ruiz et al., 2001 ), a direct influence of NMDA receptor antagonists on serotonergic neurons at the level of the dorsal raphe nucleus cannot be discarded. Indeed, the local application of MK-801 into the dorsal raphe nucleus increases the local release of 5-HT both in vitro (Callado et al., 2000) and in vivo (Tao and Auerbach, 2000) . A third alternative could be that the NMDA receptor antagonist-induced excess of cortical glutamate would act on AMPA receptors presumably located on serotonergic terminals in the mPFC, thus promoting 5-HT release. Several reports have described the presence of such AMPA receptors in the presynaptic compartment with a role in the regulation of transmitter release (Schenk and Matteoli, 2004) . Moreover, the existence of presynaptic AMPA receptors in serotonergic nerve endings has been proposed in other regions of the brain (Maione et al., 1997) although it remains to be determined in the mPFC.
The second important finding of the present study is that the increased efflux of 5-HT produced by the systemic administration of PCP and ketamine was reversed by the atypical antipsychotics clozapine and olanzapine, but not by the classical antipsychotic haloperidol. The blocking effect of olanzapine was SAL or KET delayed in comparison with that of clozapine, which may be related to differences in kinetics of the drugs. In general, atypical antipsychotics have been shown to be more effective than classical antipsychotics in reversing behavioural deficits (for review, see Jentsch and Roth, 1999) and the blockade of NMDA responses on pyramidal neurons of the mPFC (Wang and Liang, 1998) elicited by PCP. It remains to be determined, however, if the effects of clozapine and olanzapine are dependent on cortical glutamate changes. Previous research appeared to point in that direction inasmuch as clozapine tended to block glutamate efflux induced by PCP (Adams and Moghaddam, 2001 ). However, the high variability of the responses precluded any definitive conclusion. On the other hand, the effects of PCP and ketamine were antagonized by the selective a 1 -adrenoceptor antagonist prazosin. Both clozapine and haloperidol possess a similar affinity for the a 1 -adrenoceptor (Arnt and Skarsfeldt, 1998 ; Millan et al., 1998 ) and together with olanzapine are able to inhibit serotonergic cell firing in the dorsal raphe nucleus through a 1 -adrenoceptor antagonism (Millan et al., 1998 ; Sprouse et al., 1999) . Furthermore, clozapine and haloperidol occupy a similar amount (y50 %) of cortical a 1 -adrenoceptors at the doses used in the present work (Chaki et al., 1999) . Altogether these findings would suggest that, at the doses tested, the partial occupancy of a 1 -adrenoceptors is not responsible for the different effects of these drugs on the efflux of 5-HT and that these effects would not result from an inhibition of serotonergic cell firing but rather from a direct cortical action. In contrast, the dose of prazosin fully occupies brain a 1 -adrenoceptors (Patel et al., 2001) . Thus, its effects may result not only from a post-synaptic action in the mPFC since its local application in the mPFC markedly reduced 5-HT release , but also from its strong inhibition of serotonergic cell firing at the raphe level (Baraban and Aghajanian, 1980) . Nevertheless, it should be kept in mind that the sole blockade of a 1 -adrenoceptors does not posses antipsychotic action. In addition to a 1 -adrenoceptors, clozapine and olanzapine exhibit affinities much greater than that of haloperidol for 5-HT 2C receptors (Arnt and Skarsfeldt, 1998 ; Bymaster et al., 1996) . However, antagonism at 5-HT 2C receptors increases serotonergic transmission. Thus, a selective 5-HT 2C receptor antagonist (SB 242084) is able to potentiate cortical 5-HT release elicited by 5-HT reuptake blockade (Cremers et al., 2004) . This is probably the mechanism by which ritanserin slightly but significantly increased mPFC 5-HT in the present work.
Finally, clozapine and olanzapine share a high affinity for the 5-HT 2A receptor (Arnt and Skarsfeldt, 1998 ; Bymaster et al., 1996) , which suggests that this receptor could theoretically play a role in the action of these drugs in reducing the increased efflux of 5-HT evoked by PCP and ketamine. In fact, the 5-HT 2A/2C receptor antagonist ritanserin was able to abolish the effects of PCP on the 5-HT efflux, which can be predominantly attributed to its 5-HT 2A antagonistic properties (see above). In accord with our results, the selective 5-HT 2A receptor antagonist, M100907, offsets the PCP-induced hyperlocomotion, although PCP does not directly interact with 5-HT 2A receptors (Millan et al., 1999) . In addition, the pharmacological stimulation of the mPFC with S-AMPA is also reversed by 5-HT 2A receptor antagonists (Amargó s- , which suggests that the 5-HT 2A antagonism is able to counteract an excessive stimulation of AMPA receptors in the mPFC. However, ritanserin did not antagonize the ketamine-induced increase in 5-HT efflux, despite it being somewhat lower than that produced by PCP. One possibility of reconciling these apparently discordant findings is that 5-HT 2A/2C receptor blockade may be effective only in conditions of a high serotonergic tone. In accordance with this, M100907 can block MK-801-induced hyperlocomotion, but not after 5-HT depletion (Martin et al., 1998b ). The precise location of the 5-HT 2A receptors responsible for these effects remains to be determined. It is of significance that, although M100907 is able to block the effects of 5-HT 2A receptor agonists at the level of the dorsal raphe nucleus (Boothman et al., 2003) , the evidence that 5-HT cells do not express 5-HT 2A receptors (Cornea-Hébert et al., 1999 ; Pompeiano et al., 1994) further suggests that post-synaptic (possibly cortical) 5-HT 2A receptors are involved.
Regardless of the precise mechanism, it seems that the ability to prevent the NMDA receptor antagonistinduced enhancement of 5-HT efflux in the mPFC may be a characteristic of atypical antipsychotic drugs. At the dose of 1 mg/kg, it is possible that occupancy of both a 1 -adrenergic and 5-HT 2A receptors by clozapine and olanzapine may contribute to the blockade of the NMDA receptor antagonism-induced increase in cortical 5-HT efflux. Given that an overactive serotonergic transmission has been inferred to occur in schizophrenia, a reduction of 5-HT in the mPFC may be suggestive of a better antipsychotic profile for negative-cognitive symptoms. It must be taken into consideration, however, that the effects observed in the present work are limited to the pharmacological profiles of clozapine and olanzapine. While all classical antipsychotics are characterized by a predominant D 2 receptor antagonism, within the atypical class each drug possesses a distinct pharmacological profile. It is, therefore, difficult to assign the blockade of NMDA receptor antagonist-induced release of cortical 5-HT to a particular receptor interaction, although the 5-HT 2A receptor seems to have an important contribution.
